884 related articles for article (PubMed ID: 33087134)
1. Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study.
Abdo M; Watz H; Veith V; Kirsten AM; Biller H; Pedersen F; von Mutius E; Kopp MV; Hansen G; Waschki B; Rabe KF; Trinkmann F; Bahmer T
Respir Res; 2020 Oct; 21(1):278. PubMed ID: 33087134
[TBL] [Abstract][Full Text] [Related]
2. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
[TBL] [Abstract][Full Text] [Related]
3. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Impact of Sputum Inflammatory Phenotypes on Small Airway Dysfunction and Disease Outcomes in Asthma.
Abdo M; Pedersen F; Kirsten AM; Veith V; Biller H; Trinkmann F; von Mutius E; Kopp M; Hansen G; Rabe KF; Bahmer T; Watz H;
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1545-1553.e2. PubMed ID: 35257957
[TBL] [Abstract][Full Text] [Related]
6. Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma.
Yamada H; Nakajima M; Matsuyama M; Morishima Y; Arai N; Hida N; Nakaizumi T; Masuko H; Yatagai Y; Saito T; Hizawa N
PLoS One; 2021; 16(3):e0248305. PubMed ID: 33705484
[TBL] [Abstract][Full Text] [Related]
7. Assessment of spirometry and impulse oscillometry in relation to asthma control.
Manoharan A; Anderson WJ; Lipworth J; Lipworth BJ
Lung; 2015 Feb; 193(1):47-51. PubMed ID: 25516285
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
9. Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function.
Mansur AH; Srivastava S; Sahal A
Respir Med; 2018 Oct; 143():31-38. PubMed ID: 30261989
[TBL] [Abstract][Full Text] [Related]
10. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
[TBL] [Abstract][Full Text] [Related]
11. Raised sputum extracellular DNA confers lung function impairment and poor symptom control in an exacerbation-susceptible phenotype of neutrophilic asthma.
Abdo M; Uddin M; Goldmann T; Marwitz S; Bahmer T; Holz O; Kirsten AM; Trinkmann F; von Mutius E; Kopp M; Hansen G; Rabe KF; Watz H; Pedersen F;
Respir Res; 2021 Jun; 22(1):167. PubMed ID: 34082773
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
Caminati M; Cegolon L; Vianello A; Chieco Bianchi F; Festi G; Marchi MR; Micheletto C; Mazza F; Tognella S; Senna G
Expert Rev Respir Med; 2019 Dec; 13(12):1205-1212. PubMed ID: 31592700
[No Abstract] [Full Text] [Related]
13. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety Among Patients With Severe Eosinophilic Asthma Treated With Mepolizumab and Its Effect on Small Airways.
Strauss R; Leflein H; Kolesar A; Hammel J
J Allergy Clin Immunol Pract; 2023 Dec; 11(12):3670-3679.e2. PubMed ID: 37572752
[TBL] [Abstract][Full Text] [Related]
15. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study.
Postma DS; Brightling C; Baldi S; Van den Berge M; Fabbri LM; Gagnatelli A; Papi A; Van der Molen T; Rabe KF; Siddiqui S; Singh D; Nicolini G; Kraft M;
Lancet Respir Med; 2019 May; 7(5):402-416. PubMed ID: 30876830
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab Effectiveness and Allergic Status in Real Life.
Sposato B; Scalese M; Camiciottoli G; Carpagnano GE; Pelaia C; Santus P; Maniscalco M; Corsico A; Grosso A; Baglioni S; Murgia N; Folletti I; Pelaia G; Masieri S; Cavaliere C; Musarra A; Bargagli E; Ricci A; Latorre M; Paggiaro P; Rogliani P
Int Arch Allergy Immunol; 2021; 182(4):311-318. PubMed ID: 33113532
[TBL] [Abstract][Full Text] [Related]
17. Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma.
Chan R; Lipworth BJ
BMJ Open Respir Res; 2023 May; 10(1):. PubMed ID: 37208039
[TBL] [Abstract][Full Text] [Related]
18. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype.
Pelaia C; Crimi C; Pelaia G; Nolasco S; Campisi R; Heffler E; Valenti G; Crimi N
Clin Exp Allergy; 2020 Jul; 50(7):780-788. PubMed ID: 32347992
[TBL] [Abstract][Full Text] [Related]
19. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
20. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
